Cordi-B (02487): CU-20101 (injectable botulinum toxin type A) biological product marketing license application accepted by the State Drug Administration

Zhitong Finance App News, Cordi-B (02487) announced that the Group's CU-20101 (injectable type A botulinum toxin) biological product marketing license application (BLA) has been accepted by the China Drug Administration. The indication is to improve moderate to severe lines between eyebrows.

CU-20101 will not use animal-derived materials and human blood albumin in the production process, thereby eliminating the risk of infectious spongiform encephalopathy (TSE) infection and related allergic reactions, and is expected to have good safety advantages. CU-20101 will further enrich the Group's skin product matrix and facilitate the formation of synergistic effects with the Group's existing products. Facing the broad needs of the skin treatment market, the diversified product layout is expected to give the Group a larger market share.